Horizon Pharma (HZNP) PT Raised to $39 at Cowen
Get Alerts HZNP Hot Sheet
Price: $116.30 --0%
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Cowen analyst Ken Cacciatore raised the price target on Horizon Pharma (NASDAQ: HZNP) to $39.00 (from $35.00) while maintaining a Outperform rating.
The analyst commented, "Horizon's Q3 was nicely above, with the key outperformance all due to the more durable orphan portfolio, which now comprises 75% of total revenue. The primary driver was Krystexxa, which was up +42% Y/Y, and has clearly established itself as the backbone growth asset in the P&L. With Tepro set to provide meaningful P&L leverage & duration, the growth story is set to even further accelerate. Add."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades ICICI Prudential Life Insurance Co Ltd. (IPRU:IN) to Neutral
- Paramount Resources Ltd (POU:CN) (PRMRF) PT Raised to Cdn$36 at Stifel Canada
- TD Cowen Reiterates Buy Rating on Edwards Lifesciences (EW)
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!